Triflupromazine

Triflupromazine

SCHEMBL29419087

CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DRD2

The experimentally established mechanism targets of Triflupromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 6/20 0.69
LMNA P02545 11/20 1.00
MAPT P10636 10/20 1.00
TP53 P04637 7/20 1.00
NPSR1 Q6W5P4 7/20 1.00
TDP1 Q9NUW8 6/20 1.00
PMP22 Q01453 5/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
GMNN O75496 4/20 1.00
HDAC6 Q9UBN7 2/20 1.00
BLM P54132 1/20 1.00
CYP1A2 P05177 8/20 0.98
CYP2D6 P10635 8/20 0.98
HTR1A P08908 7/20 0.98
ADRA2A P08913 6/20 0.98
CHRM1 P11229 6/20 0.98
DRD1 P21728 6/20 0.98
SLC6A2 P23975 6/20 0.98
SLC6A4 P31645 6/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triflupromazine SCHEMBL317144 1.00 LMNA (1.00) LMNAMAPTTP53NPSR1TDP1
Triflupromazine SCHEMBL30903901 1.00 LMNA (1.00) LMNAMAPTTP53NPSR1TDP1
Triflupromazine SCHEMBL32668886 0.99 CYP1A2 (1.00) LMNAMAPTTP53NPSR1TDP1
Triflupromazine SCHEMBL44085 0.99 CYP1A2 (1.00) LMNAMAPTTP53NPSR1TDP1
Triflupromazine SCHEMBL317145 0.96 CYP1A2 (0.95) LMNAMAPTTP53NPSR1TDP1
SCHEMBL7750160 0.94 TP53 (0.91) LMNAMAPTTP53NPSR1TDP1
Triflupromazine SCHEMBL28057425 0.92 CYP1A2 (0.87) LMNAMAPTTP53NPSR1TDP1
SCHEMBL7346761 0.91 TP53 (0.86) LMNAMAPTTP53NPSR1TDP1
SCHEMBL23353457 0.91 TP53 (0.85) LMNAMAPTTP53NPSR1TDP1
Triflupromazine SCHEMBL9055400 0.91 TP53 (0.85) LMNAMAPTTP53NPSR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233573-A1 TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF SHIONOGI & CO (JP) 2023-07-27 US claimed
CN-218901824-U Efficient mixing equipment for producing flumioxazin 内蒙古世杰化工有限公司 2023-04-25 CN claimed
CN-114828630-A Herbicidal composition UPL有限责任公司 2022-07-29 CN claimed
WO-2022124342-A1 AGENT FOR CANCER THERAPY, AND SCREENING METHOD FOR ACTIVE INGREDIENT THEREOF 国立大学法人 岡山大学 2022-06-16 WO claimed
CN-122012456-A Cutinase variants and polynucleotides encoding same 诺维信公司 2026-05-12 CN disclosed
EP-4617666-A1 BIOMARKERS FOR GASTROINTESTINAL DISEASES IN ANIMALS Impextraco NV (BE) 2025-09-17 EP disclosed
EP-4530598-A1 BIOMARKERS FOR GASTROINTESTINAL DISEASES IN ANIMALS Impextraco NV (BE) 2025-04-02 EP disclosed
US-20240285643-A1 TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITION SHIONOGI & CO (JP) 2024-08-29 US disclosed
US-20240274877-A1 ELECTROLYTE, SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRIC APPARATUS CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) 2024-08-15 US disclosed
US-20240238306-A1 TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A COMPLICATION RISK FACTOR SHIONOGI & CO (JP) 2024-07-18 US disclosed
EP-3080254-B1 CUTINASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME NOVOZYMES AS (DK) 2024-05-15 EP disclosed
CN-113735950-B Nucleic acid molecules for imparting insecticidal properties in plants 先正达参股股份有限公司 2024-03-19 CN disclosed
WO-2022124342-A1 AGENT FOR CANCER THERAPY, AND SCREENING METHOD FOR ACTIVE INGREDIENT THEREOF 国立大学法人 岡山大学 2022-06-16 WO disclosed
US-20220142162-A1 HERBICIDAL COMPOSITIONS SYNGENTA CROP PROTECTION AG (CH) 2022-05-12 US disclosed
WO-2022095816-A1 TERNARY HERBICIDAL COMPOSITION COMPRISING CARBOXYLIC ACID DERIVATIVE-SUBSTITUTED OXYIMINOARYL COMPOUND AND USE THEREOF 青岛清原化合物有限公司 2022-05-12 WO disclosed
CN-114449894-A Herbicide combinations UPL巴西工业和农业股份公司 2022-05-06 CN disclosed
CN-114403136-A Mixed solvent mainly comprising N, N-dimethylcaproamide, and preparation method and application thereof 祺农化工科技(上海)有限公司 2022-04-29 CN disclosed
WO-2022068377-A1 BINARY HERBICIDAL COMPOSITION AND USE THEREOF 青岛清原化合物有限公司 2022-04-07 WO disclosed
CN-109310082-B Timed release granular agrochemical composition and process for producing the same 拜耳农作物科学股份公司 2022-03-29 CN disclosed
CN-114072388-A Plant growth regulator and method for promoting plant growth 株式会社吴羽 2022-02-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142162-A1 HERBICIDAL COMPOSITIONS PPOX, DDT, HPD DRD2 2342/4885LMNA 4732/4885MAPT 3851/4885
US-20240285643-A1 TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITION NEU4, IDO1, CYP3A4 DRD2 2085/4885LMNA 970/4885MAPT 4850/4885
US-20230233573-A1 TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF PNPO, IDO1, PDXK DRD2 2802/4885LMNA 1181/4885MAPT 4290/4885
US-20240274877-A1 ELECTROLYTE, SECONDARY BATTERY, BATTERY MODULE, BATTERY PACK, AND ELECTRIC APPARATUS LAGE3, SLC9B2, SLC26A3 DRD2 1578/4885LMNA 1442/4885MAPT 1913/4885
US-20240238306-A1 TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A COMPLICATION RISK FACTOR PNPO, PLPBP, CYP2C19 DRD2 3984/4885LMNA 1729/4885MAPT 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.